Kelly Doering, senior director Industry Marketing, Pharma, AspenTech, explores how pharmaceutical manufacturing should embrace change in its methods and solutions to stand out in an ever-advancing field.
Lisa Owens and Jerry Temko, managing directors, In-House Counsel Practice - Major, Lindsey & Africa, share the challenges of recruiting pharma talent in a post-Brexit climate.
Cihan Likogullari, head of sales EMEA at Envirotainer, explains why there are still barriers to the adoption of active cold-chain containers – and how they can be overcome.
Datwyler, a manufacturer of elastomer components for pharmaceutical packaging, is expanding its portfolio with two new products to meet evolving patient demands.
Ribbon Biolabs, the DNA synthesis company, announced that the U.S. Patent and Trademark Office has issued U.S. Patent US 11352619 B2, covering Ribbon Biolabs’ novel method for synthesising DNA, using a diverse library of oligonucleotides.
Almac Pharma Services’ VP Technical Operations, John McQuaid, discusses some growing requirements he sees from Almac’s client base as the industry addresses some of the trends associated with small molecule drug development.
Rebekah Jordan caught up with Cindy Reiss-Clark, chief commercial officer of West, at the recent Pharmapack show, to talk about its latest innovations and progress through the pandemic.
Mike Brown, director and containment specialist at ONFAB - part of Envair Technology - explains the growing use of HPAPIs and the demand for flexible containment that this has created.
Richard Young, vice president of Vault CDMS - Veeva Systems gives EPM some insight how a centralised data strategy can effectively manage clinical data.
Andrew Toher, head of customer insights at Enel X, discusses the sustainable energy strategies that pharma manufacturers are using to reduce carbon emissions and create valuable sources of new income.
Lonza's Conrad Roten and David Lyon explain why integrated drug substance and drug product services can help shorten First-In-Human (FIH) trial and drug commercialisation timelines.
Zeb Ahmed, CEO of BES - the specialist in design and construction of cGMP compliant pharmaceutical facilities, discusses the growing demand for sustainable built assets, why the trend is escalating and what can be done to enhance sustainability.
